Aptose Biosciences Inc. Quarterly Deferred Tax Assets, Valuation Allowance in USD from Q4 2017 to Q4 2023

Taxonomy & unit
us-gaap: USD
Description
Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.
Summary
Aptose Biosciences Inc. quarterly Deferred Tax Assets, Valuation Allowance history and growth rate from Q4 2017 to Q4 2023.
  • Aptose Biosciences Inc. Deferred Tax Assets, Valuation Allowance for the quarter ending December 31, 2023 was $91.3M, a 16.7% increase year-over-year.
Deferred Tax Assets, Valuation Allowance, Quarterly (USD)
Deferred Tax Assets, Valuation Allowance, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date Report Filed
Q4 2023 $91.3M +$13.1M +16.7% Dec 31, 2023 10-K 2024-03-26
Q4 2022 $78.2M +$10.8M +16.1% Dec 31, 2022 10-K 2024-03-26
Q4 2021 $67.4M +$15.3M +29.3% Dec 31, 2021 10-K 2023-03-24
Q4 2020 $52.1M +$10.4M +24.9% Dec 31, 2020 10-K 2022-03-22
Q4 2019 $41.7M +$12.1M +41% Dec 31, 2019 10-K 2021-03-23
Q4 2018 $29.6M +$4.53M +18.1% Dec 31, 2018 10-K 2020-03-10
Q4 2017 $25.1M Dec 31, 2017 10-K 2019-03-12
* An asterisk sign (*) next to the value indicates that the value is likely invalid.